Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial
Ke L, Zhou J, Mao W, et al. Intensive Care Medicine 2022;48:899-909.
What it found
Infected pancreatic necrosis developed in 15.7% on thymosin alpha-1 and 18.1% on placebo (difference not significant). New organ failure, bleeding and fistula rates did not differ meaningfully.
Limitations
Chinese centres only. Some authors reported fees or grants from SciClone.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.